(ANGO) AngioDynamics - Ratings and Ratios
Medical Devices, Surgical Instruments, Diagnostic Tools, Catheters, Ablation
ANGO EPS (Earnings per Share)
ANGO Revenue
Description: ANGO AngioDynamics
AngioDynamics Inc (NASDAQ:ANGO) is a medical technology company specializing in designing, manufacturing, and selling medical devices for treating peripheral vascular disease, oncology, and surgical settings globally. The companys product portfolio includes atherectomy systems, thrombus management systems, ablation systems, and peripheral products, such as angiographic catheters and guidewires.
Key products include the Auryon Atherectomy system, AlphaVac mechanical thrombectomy system, NanoKnife IRE Ablation System, and VenaCure EVLT system, which cater to various medical needs, including lesion removal, blood clot dissolution, and treatment of superficial venous disease. The companys products are designed to provide minimally invasive solutions for interventional physicians.
From a financial perspective, AngioDynamics has a market capitalization of $397.14M USD, indicating a relatively small-cap stock. The companys forward P/E ratio is 96.15, suggesting high growth expectations. However, the Return on Equity (RoE) is -21.37%, indicating that the company is currently unprofitable. Other key performance indicators (KPIs) to monitor include revenue growth, gross margin, and operating cash flow. As a trading analyst, it is essential to closely watch these metrics to assess the companys financial health and potential for future growth.
To further evaluate AngioDynamics potential, it is crucial to analyze industry trends, competitive landscape, and the companys research and development pipeline. The medical technology industry is highly competitive, and companies must innovate to stay ahead. AngioDynamics product portfolio and R&D efforts should be assessed in the context of the industrys evolving needs and competitor activity.
ANGO Stock Overview
| Market Cap in USD | 445m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2004-05-27 |
ANGO Stock Ratings
| Growth Rating | -18.1% |
| Fundamental | 23.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 19.6% |
| Analyst Rating | 4.67 of 5 |
ANGO Dividends
Currently no dividends paidANGO Growth Ratios
| Growth Correlation 3m | 28.5% |
| Growth Correlation 12m | 49.1% |
| Growth Correlation 5y | -73% |
| CAGR 5y | -19.70% |
| CAGR/Max DD 3y | -0.26 |
| CAGR/Mean DD 3y | -0.33 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.10 |
| Beta | 0.501 |
| Volatility | 51.21% |
| Current Volume | 340.4k |
| Average Volume 20d | 366.3k |
| Stop Loss | 10.4 (-4%) |
| Signal | 1.25 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-34.0m TTM) > 0 and > 6% of Revenue (6% = 17.5m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA 5.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.50% (prev 33.59%; Δ -2.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.04 (>3.0%) and CFO -10.8m > Net Income -34.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (41.0m) change vs 12m ago 1.38% (target <= -2.0% for YES) |
| Gross Margin 50.39% (prev 48.97%; Δ 1.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 97.86% (prev 95.67%; Δ 2.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -8.24
| (A) 0.33 = (Total Current Assets 168.3m - Total Current Liabilities 76.2m) / Total Assets 280.1m |
| (B) -1.53 = Retained Earnings (Balance) -429.2m / Total Assets 280.1m |
| warn (B) unusual magnitude: -1.53 — check mapping/units |
| (C) -0.11 = EBIT TTM -34.0m / Avg Total Assets 298.9m |
| (D) -4.42 = Book Value of Equity -429.2m / Total Liabilities 97.2m |
| Total Rating: -8.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.85
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -3.14% = -1.57 |
| 3. FCF Margin -5.22% = -1.96 |
| 4. Debt/Equity 0.53 = 2.36 |
| 5. Debt/Ebitda -11.80 = -2.50 |
| 6. ROIC - WACC (= -24.28)% = -12.50 |
| 7. RoE -18.08% = -2.50 |
| 8. Rev. Trend -64.36% = -4.83 |
| 9. EPS Trend -3.05% = -0.15 |
What is the price of ANGO shares?
Over the past week, the price has changed by -1.01%, over one month by +23.35%, over three months by +6.59% and over the past year by +41.75%.
Is AngioDynamics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANGO is around 9.16 USD . This means that ANGO is currently overvalued and has a potential downside of -15.42%.
Is ANGO a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.3 | 68.5% |
| Analysts Target Price | 18.3 | 68.5% |
| ValueRay Target Price | 10 | -7.4% |
Last update: 2025-09-12 04:31
ANGO Fundamental Data Overview
CCE Cash And Equivalents = 55.9m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 96.1538
P/S = 1.5198
P/B = 2.4451
P/EG = 1.87
Beta = 0.637
Revenue TTM = 292.5m USD
EBIT TTM = -34.0m USD
EBITDA TTM = -8.23m USD
Long Term Debt = 21.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 76.2m USD (from totalCurrentLiabilities, last quarter)
Debt = 97.2m USD (Calculated: Short Term 76.2m + Long Term 21.0m)
Net Debt = -55.9m USD (from netDebt column, last quarter)
Enterprise Value = 485.8m USD (444.5m + Debt 97.2m - CCE 55.9m)
Interest Coverage Ratio = unknown (Ebit TTM -34.0m / Interest Expense TTM 0.0)
FCF Yield = -3.14% (FCF TTM -15.3m / Enterprise Value 485.8m)
FCF Margin = -5.22% (FCF TTM -15.3m / Revenue TTM 292.5m)
Net Margin = -11.62% (Net Income TTM -34.0m / Revenue TTM 292.5m)
Gross Margin = 50.39% ((Revenue TTM 292.5m - Cost of Revenue TTM 145.1m) / Revenue TTM)
Tobins Q-Ratio = -1.13 (set to none) (Enterprise Value 485.8m / Book Value Of Equity -429.2m)
Interest Expense / Debt = 0.58% (Interest Expense 567.0k / Debt 97.2m)
Taxrate = 21.0% (US default)
NOPAT = -34.0m (EBIT -34.0m, no tax applied on loss)
Current Ratio = 2.21 (Total Current Assets 168.3m / Total Current Liabilities 76.2m)
Debt / Equity = 0.53 (Debt 97.2m / last Quarter total Stockholder Equity 183.0m)
Debt / EBITDA = -11.80 (Net Debt -55.9m / EBITDA -8.23m)
Debt / FCF = -6.36 (Debt 97.2m / FCF TTM -15.3m)
Total Stockholder Equity = 188.0m (last 4 quarters mean)
RoA = -12.13% (Net Income -34.0m, Total Assets 280.1m )
RoE = -18.08% (Net Income TTM -34.0m / Total Stockholder Equity 188.0m)
RoCE = -16.28% (Ebit -34.0m / (Equity 188.0m + L.T.Debt 21.0m))
RoIC = -17.75% (NOPAT -34.0m / Invested Capital 191.7m)
WACC = 6.53% (E(444.5m)/V(541.7m) * Re(7.86%)) + (D(97.2m)/V(541.7m) * Rd(0.58%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.38%
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -15.3m)
EPS Correlation: -3.05 | EPS CAGR: 9.61% | SUE: 1.47 | # QB: 5
Revenue Correlation: -64.36 | Revenue CAGR: -2.52% | SUE: 0.0 | # QB: 0
Additional Sources for ANGO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle